Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

Cathalijne C.B. Post; Stephanie M. de Boer; Melanie E. Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Alexandra Leary; Petronella B. Ottevanger; Mary McCormack; Pearly Khaw; Romerai D’Amico; Anthony Fyles; Cyrus Chargari; Henry C. Kitchener; Viet Do; Andrea Lissoni; Diane Procencher; Catherine Genestrie; Hans W. Nijman; Karen Whitmarsh; Ina M. Jürgenliemk-Schulz; Amanda Feeney; Ludy C.H.W. Lutgens; Jeanette Bouma; Alicia Leon-Castillo; Remi A. Nout; Hein Putter; Tjalling Bosse; Carien L. Creutzberg

doi:10.1097/OGX.0000000000001475

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

Cathalijne C.B. Post
, Stephanie M. de Boer
, Melanie E. Powell
, Linda Mileshkin
, Dionyssios Katsaros
, Paul Bessette
, Alexandra Leary
, Petronella B. Ottevanger
, Mary McCormack
, Pearly Khaw
, Romerai D’Amico
, Anthony Fyles
, Cyrus Chargari
, Henry C. Kitchener
, Viet Do
, Andrea Lissoni
, Diane Procencher
, Catherine Genestrie
, Hans W. Nijman
, Karen Whitmarsh

Ina M. Jürgenliemk-Schulz, Amanda Feeney, Ludy C.H.W. Lutgens, Jeanette Bouma, Alicia Leon-Castillo, Remi A. Nout, Hein Putter, Tjalling Bosse, Carien L. Creutzberg

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

(Abstracted from Lancet Oncol 2025;26(10):1370–1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.

Original language	English
Pages (from-to)	757-759
Number of pages	3
Journal	Obstetrical and Gynecological Survey
Volume	80
Issue number	12
DOIs	https://doi.org/10.1097/OGX.0000000000001475
Publication status	Published - Dec 2025

Access to Document

10.1097/OGX.0000000000001475

adjuvant_chemoradiotherapy_versus_radiotherapy.12Final published version, 77.1 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial'. Together they form a unique fingerprint.

Cite this

Post, C. C. B., de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Leary, A., Ottevanger, P. B., McCormack, M., Khaw, P., D’Amico, R., Fyles, A., Chargari, C., Kitchener, H. C., Do, V., Lissoni, A., Procencher, D., Genestrie, C., Nijman, H. W., ... Creutzberg, C. L. (2025). Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. Obstetrical and Gynecological Survey, 80(12), 757-759. https://doi.org/10.1097/OGX.0000000000001475

Post, Cathalijne C.B. ; de Boer, Stephanie M. ; Powell, Melanie E. et al. / Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) : 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. In: Obstetrical and Gynecological Survey. 2025 ; Vol. 80, No. 12. pp. 757-759.

@article{08a5d5ef3d6d4e54a437a176e1c3bce6,

title = "Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial",

abstract = "(Abstracted from Lancet Oncol 2025;26(10):1370–1381) Fifteen percent to 20\% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.",

author = "Post, \{Cathalijne C.B.\} and \{de Boer\}, \{Stephanie M.\} and Powell, \{Melanie E.\} and Linda Mileshkin and Dionyssios Katsaros and Paul Bessette and Alexandra Leary and Ottevanger, \{Petronella B.\} and Mary McCormack and Pearly Khaw and Romerai D{\textquoteright}Amico and Anthony Fyles and Cyrus Chargari and Kitchener, \{Henry C.\} and Viet Do and Andrea Lissoni and Diane Procencher and Catherine Genestrie and Nijman, \{Hans W.\} and Karen Whitmarsh and J{\"u}rgenliemk-Schulz, \{Ina M.\} and Amanda Feeney and Lutgens, \{Ludy C.H.W.\} and Jeanette Bouma and Alicia Leon-Castillo and Nout, \{Remi A.\} and Hein Putter and Tjalling Bosse and Creutzberg, \{Carien L.\}",

year = "2025",

month = dec,

doi = "10.1097/OGX.0000000000001475",

language = "English",

volume = "80",

pages = "757--759",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams \& Wilkins",

number = "12",

}

Post, CCB, de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Leary, A, Ottevanger, PB, McCormack, M, Khaw, P, D’Amico, R, Fyles, A, Chargari, C, Kitchener, HC, Do, V, Lissoni, A, Procencher, D, Genestrie, C, Nijman, HW, Whitmarsh, K, Jürgenliemk-Schulz, IM, Feeney, A, Lutgens, LCHW, Bouma, J, Leon-Castillo, A, Nout, RA, Putter, H, Bosse, T & Creutzberg, CL 2025, 'Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial', Obstetrical and Gynecological Survey, vol. 80, no. 12, pp. 757-759. https://doi.org/10.1097/OGX.0000000000001475

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. / Post, Cathalijne C.B.; de Boer, Stephanie M.; Powell, Melanie E. et al.
In: Obstetrical and Gynecological Survey, Vol. 80, No. 12, 12.2025, p. 757-759.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3)

T2 - 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

AU - Post, Cathalijne C.B.

AU - de Boer, Stephanie M.

AU - Powell, Melanie E.

AU - Mileshkin, Linda

AU - Katsaros, Dionyssios

AU - Bessette, Paul

AU - Leary, Alexandra

AU - Ottevanger, Petronella B.

AU - McCormack, Mary

AU - Khaw, Pearly

AU - D’Amico, Romerai

AU - Fyles, Anthony

AU - Chargari, Cyrus

AU - Kitchener, Henry C.

AU - Do, Viet

AU - Lissoni, Andrea

AU - Procencher, Diane

AU - Genestrie, Catherine

AU - Nijman, Hans W.

AU - Whitmarsh, Karen

AU - Jürgenliemk-Schulz, Ina M.

AU - Feeney, Amanda

AU - Lutgens, Ludy C.H.W.

AU - Bouma, Jeanette

AU - Leon-Castillo, Alicia

AU - Nout, Remi A.

AU - Putter, Hein

AU - Bosse, Tjalling

AU - Creutzberg, Carien L.

PY - 2025/12

Y1 - 2025/12

N2 - (Abstracted from Lancet Oncol 2025;26(10):1370–1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.

AB - (Abstracted from Lancet Oncol 2025;26(10):1370–1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.

UR - https://www.scopus.com/pages/publications/105035428460

U2 - 10.1097/OGX.0000000000001475

DO - 10.1097/OGX.0000000000001475

M3 - Article

C2 - 41373150

AN - SCOPUS:105035428460

SN - 0029-7828

VL - 80

SP - 757

EP - 759

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 12

ER -

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P et al. Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. Obstetrical and Gynecological Survey. 2025 Dec;80(12):757-759. doi: 10.1097/OGX.0000000000001475

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this